New data show potential for PBT434 to treat MSA
Filed with ASX · · 2 pages · English
Alterity Therapeutics Ltd. on 6ix
Earlier from Alterity Therapeutics
- Annual Report to shareholders
- Prana to present PBT434 data at International Congress
- First Volunteers Dosed in Phase I Clinical Trial of PBT434
- Prana to commence Phase 1 clinical trial of PBT434
- PBT434 at the 6th International Multiple System Atrophy Conf
Later from Alterity Therapeutics
- Life Bioscience LLC leads strategic investment upto A$44.5M
- Orphan Designation for PBT434 for treatment of MSA
- Prana receives A$3.3 million R&D Tax Incentive Refund
- Alterity presents initial Phase 1 clinical trial data at AAN
- Successful Completion of Phase 1 Clinical Trial
Follow Alterity Therapeutics into a list and get an email when it puts out news.
Follow Alterity Therapeutics